Abstract Library

#4227 Evaluation of circulating extracellular vesicles as suitable prognostic markers in MEN1-associated non-functioning pancreatic neuroendocrine neoplasia

Introduction: Non-functioning pancreatic neuroendocrine neoplasias (NF-pNENs) significantly contribute to premature death of multiple endocrine neoplasia type 1 (MEN1) patients. Reliable prognostic markers for disease progression are lacking. Circulating liquid biomarkers, including microRNAs and Long-non-Coding (LnC) RNAs in extracellular vesicles, are emerging as new prognostic tools.

Conference:

Presenting Author:

Authors: Manoharan J, Khizanishvili N, Krasser-Gercke N, Albers M, Mintziras I,

Keywords: Multiple endokrine neoplasia type 1, Extracellular vesicles, Non-functioning pancreatic neuroendocrine neoplasia, exosomal-LnC-RNA NEAT1, exosomal miRNA451a,

#4174 Uncovering the genomic profiling of metastatic pheochromocytomas and paragangliomas: Leveraging plasma circulating tumor DNA for comprehensive genetic characterisation and monitoring

Introduction: Liquid biopsy, notably plasma circulating tumor DNA (ctDNA), is a non-invasive approach to elucidate the tumoral genomic profile from a blood sample. Pheochromocytomas and paragangliomas (PPGL) are often operated, characterized by quiet genomes and usually indolent tumor growth. However, challenges arise with metastatic tumors due to accessibility, catecholamine-related crises and surgery issues. Thus, molecular mechanisms transitioning from indolent to metastatic tumors are largely unexplored.

Conference:

Presenting Author:

Authors: Arenillas Lallana C, Moreno-Cárdenas A, Casteràs A, García-Álvarez A, Hernando J,

Keywords: liquid biopsy, ctDNA, metastasis, pheochromocytoma, paraganglioma, genomic targets,

#4161 177Lu-DOTATATE (177Lu) efficacy in metastatic well-differentiated neuroendocrine tumors (wdNET): Differences in response according to metastases (met) location

Introduction: Treatment with 177Lu is standard of care for wdNET with high somatostatin receptor expression. Patterns of response could differ between hepatic (hep) and extrahepatic (ehep) met.

Conference:

Presenting Author:

Authors: Sánchez Gómez L, Guillén Sentís P, Ruffinelli J, Torrent F, Vercher Conejero J,

Keywords: 177lu-dotatate, well-differentiated neuroendocrine tumor, tumor growth rate,

#3928 MEN1 deficiency-induced the activation of β-Catenin-MGMT axis promotes Pancreatic Neuroendocrine Tumor growth and disrupts the response to Temozolomide

Introduction: O6-methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6-MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ).

Conference:

Presenting Author: Ji S

Authors: Ji S, Xu J, Wang F, Lou X, Ye Z,

Keywords: Pancreatic neuroendocrine tumor, MGMT, MEN1, Temozolomide tolerance,

#3778 Biological behaviour and response to treatment of neuroendocrine ovarian metastases

Introduction: Neuroendocrine ovarian metastases (NOM) predominantly derive from midgut neuroendocrine tumors (NETs) and develop in about 25% of female patients. Little is known of the treatment response of NOM.

Conference:

Presenting Author:

Authors: Mulders M, de Lussanet de La Sablonière Q, van Velthuysen M, Hofland J, de Herder W,

Keywords: neuroendocrine, ovary, PRRT, SSA, oophorectomy, tumor, growth, rate, PFS, OS,